Levi & Korsinsky, LLP announces that a CCXI class action lawsuit has been filed on behalf of investors who purchased ChemoCentryx, Inc. (CCXI) securities between November 26, 2019 and May 3, 2021. For more on the CCXI Lawsuit please contact us today.
According to the ChemoCentryx, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s New Drug Application (“NDA”) for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in ChemoCentryx, Inc. you have until July 6, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.